Stay updated on Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.

Latest updates to the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No user-facing content or study information was changed.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Revision: v3.5.0 and removed Interstitial lung disease 2, the Genetic and Rare Diseases Information Center resource, and Revision: v3.4.3.SummaryDifference0.2%

- Check38 days agoChange DetectedRevision updated to v3.4.3; the previous revision v3.4.2 has been removed.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page now shows Revision: v3.4.2, and the older funding-related notice (v3.4.1) has been removed.SummaryDifference0.4%

- Check73 days agoChange DetectedAdded a government funding notice banner at the top of the page and updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedAdded a glossary toggle, normalized capitalization for QC-related labels and No FEAR Act text, and updated the page revision to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Tolerability PK of Nintedanib with Pirfenidone in IPF Clinical Trial page.